Siuliana Limasi

AVM is a development-stage biotech company advancing the research, development and commercialization of game-changing stem cell technologies for high unmet medical needs in regenerative medicine, cancer treatment recovery, safer iPS cell culturing and treatment, and fully human biologics, including patient-specific biologics for personalized medicine (“Boutique Biologics™”) in orphan diseases.